How can these analysts justify their existence other than to make judgments without reasons - they state downgraded to market perform but slash pricing when little financial changes and the hold on #427 is a normal situation which could be waived very shortly. Based on other stocks and the eps and the pipeline the pricing should be in the low teens.
It's just the typical manipulation.
Smart Money wants a lower entry.
It seems to me that the clinical hold will be temporary.
Besides, the real deal here is the PII trial in advanced operable BCC.
Results in Q1 2014.